Liver Cancer Clinical Trial
Official title:
TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer
Verified date | May 2011 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | Unspecified |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking
the blood flow to the tumor. Sorafenib tosylate may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
It is not yet known whether transarterial chemoembolization using doxorubicin-eluting beads
is more effective when given with or without sorafenib tosylate in treating patients with
liver cancer that cannot be removed by surgery.
PURPOSE: This randomized phase III trial is studying giving transarterial chemoembolization
using doxorubicin-eluting beads and sorafenib tosylate to see how well it works compared
with giving transarterial chemoembolization using doxorubicin-eluting beads and a placebo in
treating patients with liver cancer that cannot be removed by surgery.
Status | Recruiting |
Enrollment | 412 |
Est. completion date | |
Est. primary completion date | November 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed hepatocellular carcinoma (HCC) OR meets the American Association for the Study of Liver Diseases (AASLD) criteria for diagnosis of HCC - Unresectable disease - Not amenable to liver transplantation - At least one uni-dimensionally measurable lesion according to the RECIST criteria by CT scan or MRI - Child-Pugh A (score = 6) and no Child-Pugh cirrhosis C or B (score = 7) - No ascites refractory to diuretic therapy - No documented occlusion of the hepatic artery or main portal vein - No extrahepatic metastasis or hepatic encephalopathy PATIENT CHARACTERISTICS: - ECOG performance status 0-1 - Life expectancy > 3 months - Hemoglobin = 9 g/L - Absolute neutrophil count = 1.5 x 10^9/L - Platelet count = 60,000/µL - Bilirubin = 50 µmol/L - Alkaline phosphatase < 4 times upper limit of normal (ULN) - AST and ALT < 5 times ULN - Creatinine = 1.5 times ULN - Amylase and lipase < 2 times ULN - INR = 1.5 - LVEF = 45% - Able to swallow oral medication - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during study and for 3 months after completion of study treatment - No history of bleeding within the past 4 weeks - No contraindications for hepatic embolization procedures, including portosystemic shunt, hepatofugal blood flow, or known severe atheromatosis - No hypersensitivity to intravenous contrast agents - No active clinically serious infection > grade 2 (NCI-CTC version 4) - No known history of HIV infection - No history of second malignancy except non-melanotic skin cancer or cervical carcinoma in situ or malignancy treated with curative intent with > 3 years without relapse - No evidence of severe or uncontrolled disease including any of the following: - Systemic disease - Cardiac arrhythmias (requiring anti-arrhythmic therapy or pacemaker) - Hypertension - NYHA class III or IV congestive cardiac failure - Myocardial infarction within the past 6 months - Laboratory finding that, in the view of the Investigator, makes it undesirable for the patient to participate in the trial - No psychiatric or other disorder likely to impact on informed consent PRIOR CONCURRENT THERAPY: - At least 4 weeks since prior and no concurrent investigational therapy - No prior embolization, systemic therapy, or radiotherapy for HCC - No major surgery within the past 4 weeks - No ablative therapy (radiofrequency ablation or percutaneous ethanol injection) for HCC - Patients with untreated target lesion(s) and ablation occurred > 6 weeks prior to study entry allowed - No concurrent rifampicin or St. John wort - No concurrent bone marrow transplant or stem cell rescue - No concurrent bevacizumab or drugs that target VEGF or VEGF receptors - No other concurrent anticancer chemotherapy, immunotherapy, hormone therapy, or molecular therapy except bisphosphonates |
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust | Birmingham | England |
United Kingdom | Bristol Royal Infirmary | Bristol | England |
United Kingdom | Aintree University Hospital | Liverpool | England |
United Kingdom | King's College Hospital | London | England |
United Kingdom | Royal Free Hospital | London | England |
United Kingdom | Royal Marsden - London | London | England |
United Kingdom | Queen's Medical Centre | Nottingham | England |
United Kingdom | Southampton General Hospital | Southampton | England |
Lead Sponsor | Collaborator |
---|---|
University College, London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival | No | ||
Secondary | Overall survival | No | ||
Secondary | Time to progression | No | ||
Secondary | Toxicity | Yes | ||
Secondary | Disease control (complete or partial response or stable disease) | No | ||
Secondary | Quality of life | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Recruiting |
NCT05160740 -
Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer
|
N/A | |
Completed |
NCT01906021 -
Study of New Software Used During Ablations
|
N/A | |
Terminated |
NCT04589884 -
Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
|
||
Recruiting |
NCT05953337 -
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
|
N/A | |
Enrolling by invitation |
NCT04466124 -
Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
|
||
Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT03059238 -
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
|
Phase 3 | |
Recruiting |
NCT02632188 -
Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT01388101 -
Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor)
|
N/A | |
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Completed |
NCT00980239 -
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
|
Phase 1 | |
Completed |
NCT01042041 -
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
|
Phase 1 | |
Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
Completed |
NCT00543777 -
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
|
Phase 1/Phase 2 |